Evaluation of pharmacotherapy protocols for COVID 19 patients in Baqiyatallah Hospital and their outcomes

The propagation of new coronavirus, COVID 19, is still a major priority for the many countries around the word. Because of absence of any effective treatment for COVID 19. The special medicinal protocols are needed in medical centers to reduce mortality rate. Due to constant change of national pharmacotherapy protocols for COVID-19 patients, this study compares the outcomes of three specific pharmacotherapy regimens and the combination of all 3 regimens for management of 614 COVID-19 patients which hospitalized in Baqiyatallah hospital in Tehran, this hospital became a referral centers for receiving COVID 19 patients in Iran. The more reliable result of treatments belong to regimen 3 which indicated to 98.26% recovered patients and 1.15% mortality rate and the lowest period of hospitalization with 4.4±0.21 days’ duration. It seems that regimen 3 (with special combination of antiviral and Azithromycin ant anti-inflammatory drugs) had the best result in improving patients with COVID 19 and furthermore this result has not conflict with comorbidity status of patients.